# MEOI and HRQoL in CLL Patients Treated With BTKis

> **NCT04938141** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 23 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04938141
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-07
- **Primary completion:** 2024-09-26
- **Final completion:** 2024-09-26
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04938141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04938141, "MEOI and HRQoL in CLL Patients Treated With BTKis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04938141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*